Skip to main content

10-year data suggest bears dominated the Street in November; what to expect in 2020?

A favorable outcome of the US elections results will result in a risk-on environment which will lead to strong FPI flows for India, suggest experts.

The Indian market might have rallied by over 2 percent so far in November, but historical data suggest bears have mostly controlled the D-Street.

The Nifty50 is back above 11,900 levels but experts feel that investors should stay cautious amid US election results as well as a rise in COVID cases across the globe.

The Nifty50 rallied more than 3 percent in October and the momentum looks strong at least in the first week of November, but as we approach crucial resistance levels above 12000 some more consolidation is expected before the index breakout into unchartered territory.

Looking at the historical data, Nifty has given positive returns in October in four of the last 10 years. The index rose over 6 percent in November 2018, followed by 2014 when it gained 5.13 percent, and in 2012, Nifty50 closed with gains of 5.04 percent in November, data from AceEquity showed.

The index closed in the red in 6 out of the last 10 years. The index fell nearly 10 percent in November 2011, 4.6 percent in 2016, and a 2.5 percent fall was seen in 2010 for the month of November.


“We believe that the outlook for November is a mixed bag and a lot will depend on the outcome of the US elections. A favorable outcome of the US elections results will result in a risk-on environment which will lead to strong FPI flows for India,” Jyoti Roy, DVP Equity Strategist, Angel Broking Ltd told Moneycontrol.

“An adverse outcome of the US elections on the other hand will result in a global risk-off environment which will lead to FIIs pulling out money from India and put pressure on the markets,” he said.

Roy further added that there is also the probability of the results being challenged in the US Supreme Court which could lead to volatility in the markets.

Experts are of the view that with economic activity picking up, and September earnings meeting expectations, experts feel that the rally could continue in select stocks but index could face marginal selling pressure at higher levels.

“Most of the companies performed very well in the September quarter and are expected to perform better as economic activities open up,” Atish Matlawala, Sr Analyst, SSJ Finance & Securities told Moneycontrol.

“However, valuations at current levels look a little stretched and we believe markets need to consolidate before making a fresh up move,” he said.

Events that will impact stock markets in November include the outcome of the US Presidential elections, the outcome of the FOMC meeting, the second wave of lockdown, macro and microeconomic data.

Institutional Flows:

Institutional activity picked up in November. Anecdotal evidence suggests that foreign institutional investors (FIIs) were net buyers in Indian markets in six of the last 10 years.

FIIs poured in over Rs 22,000 crore in November 2019, followed by Rs 19,000 crore in 2017, and over Rs 18,000 crore in 2010.

FPI flows will be a function of the outcome of the US elections along with progress on the second stimulus package and news flow on the Covid and vaccine front, suggest experts.



“Any positive development on the US stimulus package and the vaccine front can trigger a risk on environment globally which will lead to strong FPI flows,” says Roy of Angel Broking Ltd.

“However, any adverse outcome of the US elections which leads to a delay in the second US stimulus package or negative news flow on the vaccine front can trigger a risk-off environment which will result in FPIs pulling money out of Indian equities,” he said.

Source - Moneycontrol.com

 

Comments

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...

Brokerages place bets on Titan, see double-digit upside in the stock

Titan can get benefits from the strong market share in the jewellery and wrist watches segment, mainly driven by a wide range of product portfolio catering mainly to the premium and value-added designer jewellery segment. After three consecutive sessions of losses, shares of Titan Company rose over a percent in morning trade on BSE on September 23. The company was dealt a severe blow by COVID-19 as the pandemic triggered strict lockdowns completely battered the retail sector. In the calendar year so far, shares of this one of the largest, most efficient and profitable specialty retailer in India are 7 percent down. The company reported a net standalone loss of Rs 270 crore for the quarter ended June 2020 as the COVID-19 pandemic hit business. The loss was higher than a CNBC-TV18 poll estimate of Rs 175 crore. Standalone revenue during the quarter declined 62.3 percent year-on-year to Rs 1,862 crore compared to the corresponding period last fiscal. Light at the end ...

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...